Stay informed with the latest pharma industry news and insights by signing up for PharmaVoice. Explore all our free newsletter options here: https://lnkd.in/gP2m_c7J
PharmaVoice
Pharmaceutical Manufacturing
Washington, District of Columbia 11,535 followers
Covering everything from Molecule to Market
About us
PharmaVoice is for life-sciences executives and other healthcare-service related professionals. The primary audience is made up of executive and corporate management from pharmaceutical, biotechnology, drug delivery, marketing communications, clinical services, contract research, drug development, and information technology companies, as well as other industry sectors. Additionally, PharmaVoice.com has readers from around the world. Subscribe to the daily newsletter at https://dive.pub/3ruPmUL
- Website
-
http://www.pharmavoice.com
External link for PharmaVoice
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Washington, District of Columbia
- Type
- Privately Held
- Specialties
- pharmaceutical, biotechnology, medical devices, life sciences, advertising, marketing, publishing, digital media, editorial, content generation, digital marketing, and marketing strategy
Locations
-
Primary
1100 15th St NW
4th Floor - (Suite 178)
Washington, District of Columbia 20005, US
Employees at PharmaVoice
Updates
-
Pharma might be emerging from an "age of uncertainty" as the path forward becomes clearer and even certain headwinds come into better focus, according to a report from Evaluate Ltd. Read more at PharmaVoice.
Has pharma emerged from the ‘age of uncertainty’?
pharmavoice.com
-
Bristol Myers Squibb could soon see some headwinds for its blockbuster leukemia drug #Sprycel as the first generic is expected to hit the market in September. #pharma #patents #generics https://lnkd.in/euuBts4S
BMS’ long-standing leukemia blockbuster stares down its first generic
pharmavoice.com
-
Pharma executives and lobbyists have long sought to shift the blame for U.S. drug costs to the industry’s price-negotiating middlemen known as pharmacy benefit managers. “Last year, about 80% of our insulin list prices went to paying fees and rebates to companies who didn’t invent, develop, manufacture nor study the medicine,” Eli Lilly and Company CEO Dave Ricks said at the May 2023 congressional hearing. Now, a new FTC report might provide drugmakers some validation. #pharma #PBM Federal Trade Commission National Community Pharmacists Association (NCPA) Douglas Hoey Pharmaceutical Care Management Association (PCMA) https://lnkd.in/dyct-8Pd
As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat
pharmavoice.com
-
With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and foster new health benefits. #GLP1 #obesity #semaglutide #ozempic Ivim Health Xevant Nestlé Health Science Dandelion Health https://lnkd.in/eMkCn3w5
As the GLP-1 market booms, other healthcare companies are cashing in
pharmavoice.com
-
Recent history suggests an Alzheimer’s approval doesn’t necessarily translate to market triumph. Perhaps for Eli Lilly and Company’s Kisunla, this time could be different. “Any new treatment in the Alzheimer’s area is providing some hope to that community,” says Jayne Hornung, chief clinical officer at MMIT (Managed Markets Insight & Technology). #ALZ #donanemab Michael Gibney https://lnkd.in/exg-XQ8T
FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.
pharmavoice.com
-
The FDA has taken another tangible step to boosting #diversity in clinical trials. The agency recently released a long-awaited draft guidance revealing more details about how sponsors can create Diversity Action Plans to enroll trial participants who more fully represent the people using products once they hit the market. Rohit Nambisan Julie Ozier https://lnkd.in/exjw42Ra
The FDA pushes concrete plans to further diversity in clinical trials
pharmavoice.com
-
Neuroscience pipelines are reawakening as biotechs prove to the pharma giants that the field is still worth the investment. “We’re seeing a resurgence of interest in central nervous system disorders, and for folks that have been in that space for some time, we’re delighted to see investment coming back," says Gene Kinney, CEO of Prothena Corporation. #biotech #brain #CNS Karuna Therapeutics Bristol Myers Squibb GSK Celgene Pfizer Novartis AstraZeneca https://lnkd.in/gUpTtiC7
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
pharmavoice.com
-
In pharma and biotech, success is measured in decades. For Geron Corporation's blood #cancer treatment, Rytelo, the road to approval was 33 years, including “about 20 years of development in patients,” according to Faye Feller, Geron's chief medical officer. “We’ve had a strong belief in bringing this mechanism to patients that has really persisted,” she told PharmaVoice. #drugdevelopment #oncology #firstinclass https://lnkd.in/e247ACPF
After 33 years, Geron’s first approval marks a turn in Nobel-winning science
pharmavoice.com
-
Weight loss market leaders Eli Lilly and Company and Novo Nordisk are warning patients and healthcare providers about the risks associated with knockoff versions of their popular #obesity meds — and taking legal action. #ozempic #mounjaro #GLP1 #wegovy #zepbound https://lnkd.in/eSWdKPHC
Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle
pharmavoice.com